We have characterized the spectrum of SLC26A4 mutations and clinical features in a population of mainland Chinese patients with nonsyndromic sensorineural hearing loss (SNHL) and enlarged vestibular aqueduct (EVA). STUDY DESIGN: Cross-sectional clinical genetic study. SETTING: Tertiary care outpatient otolaryngology clinic. METHODS: A total of 32 subjects identified with bilateral EVA using high-resolution CT were screened for mutations in SLC26A4 by denaturing high-performance liquid chromatography and direct sequencing methods. RESULTS: A total of 13 different mutations were identified in the SLC26A4 gene, five of which are novel. A total of 88 percent of the patients harbored biallelic mutations, 11 patients were homozygotes, and 17 were compound heterozygotes. Four patients were found to carry a single SLC26A4 mutation. The IVS7-2AϾG mutation was the most frequent, accounting for 60 percent of the mutant alleles. We have not found any correlations between the type of SLC26A4 mutations and the type, degree, and progression of hearing loss. There are significant proportions of patients with asymmetric (26%), progressive (32%), or fluctuating hearing loss (21%). CONCLUSION: Our data confirm the high prevalence of SLC26A4 mutations in Chinese patients with SNHL and EVA. We could not establish any relationship between genotype and phenotype. However, the high incidence of asymmetric, progressive, and fluctuating hearing loss found in the current study indicates that patients with those features should be routinely screened for SLC26A4 mutation in addition to diagnosis of EVA using CT or MRI.
chromosome 7, the SLC26A4 gene is made up of 21 exons. The encoded protein, pendrin, is expressed in nonsensory cells in the cochlear scala media, thyroid, renal, uterine, and placental tissue. Pendrin is thought to be involved in anion transport, although it remains unclear how this leads to cochlear dysfunction. Enlargement of the vestibular aqueduct is the most common anomaly associated with mutations of SLC26A4 and is genetically characterized as a nonsyndromic autosomal recessive disorder (DFNB4, OMIM 600791). The molecular genetic basis for the hearing loss associated with EVA was investigated in different ethnic populations. It is clear that EVA is associated with mutations of the SLC26A4 (PDS) gene in many racial populations. More than 150 SLC26A4 mutations have been described in different populations.
In the present study, we screened DNA for SLC26A4 mutations in a Chinese cohort of deaf probands with SNHL and EVA. Using the audiological classification criteria of genetic deafness proposed by the European Workshop on Genetic Hearing Loss, 1 we analyzed audiological data to characterize the clinical features and spectrum of SLC26A4 mutations in the mainland Chinese patients.
MATERIALS AND METHODS

Subjects and Audiology
From a Chinese cohort of patients with suspected genetic hearing loss, we identified 32 subjects (three from multiplex and 29 from simplex families) with EVA using high-resolution CT (HRCT) in the Department of Otolaryngology, Head and Neck Surgery, Chinese People's Liberation Army General Hospital (Beijing, China). The project was approved by the Ethic Committee of Chinese PLA General Hospital. Written informed consent was obtained from all of the participants before donation of a blood sample. The criterion for the diagnosis of EVA was a vestibular aqueduct diameter Ͼ 1.5 mm measured midway between the opercu-lum and the common crus. 2 All subjects were examined otoscopically, and pure-tone audiometry was performed as well as immittance testing (tympanometry and acoustic reflexes) for assessment of the integrity and function of the middle ear. Air conduction thresholds were measured at 250, 500, 1, 2, 4, 6, and 8 k Hz and bone conduction thresholds at 0.5, 1, 2, 4, and 6 k Hz. When output of the bone conduction audiometer was beyond the vibration perception threshold in the pure tone test, we were not able to determine whether patients perceived sound or vibration; for example, the vibration perception threshold on the mastoid process at 250 Hz is about 40 dB HL. Therefore, we ended the test when the output of the bone conduction reached 40, 50, 60, 60, and 60 dB HL at 250, 500, 1000, 2000, and 4000 Hz, respectively. For this reason, the maximum output of the machine is always designed to be limited within 70 dB, and the air-bone gaps (ABGs) were not obtained for 1000, 2000, and 4000 Hz. The results of the pure tone audiograms were analyzed by using the audiological classification criteria of genetic deafness proposed by the European Workshop on Genetic Hearing Loss. The severity of hearing impairment was applied to the betterhearing ear, averaged over 0.5, 1, 2, and 4 k Hz, and was categorized as follows: mild, Ͼ20 dB and Յ40 dB; moderate, Ͼ40 dB and Յ70 dB; severe, Ͼ70 dB and Յ95 dB; profound, Ͼ95 dB. Asymmetry is defined by Ͼ10 dB difference between the ears in at least two frequencies with a difference in the pure tone average between the ears of Ͼ20 dB; progression is a deterioration of Ͼ15 dB in the pure tone average within a 10-year period. A comprehensive history inquiry and physical examination were performed on all subjects to exclude cases of syndromic deafness or those induced by environmental causes (eg, aminoglycoside-induced or infections).
Mutation Analysis
A genomic DNA sample of each subject was extracted from whole blood with a DNA Blood Kit (Watson Biotechnologies Inc, Shanghai, China). All 21 exons and the intron-exon boundaries of the SLC26A4 gene were sequenced in each of the subjects who had an EVA. In addition, a total of 200 matched controls of Chinese background with normal hearing were screened for SLC26A4 mutation by denaturing high-performance liquid chromatography (DHPLC) followed by direct sequencing of amplicons with abnormal elution profiles. In brief, DNA samples were first amplified by polymerase chain reaction (PCR) using primers flanking each exon. PCR was conducted in a 20 L reaction volume solution, which contained 40 ng of genomic DNA, 400 M deoxyribonucleotide triphosphate, 1.25 units of proTaq DNA polymerase, 0.2 M intragenic primers, and 2.5 mM magnesium chloride. Sequencing was performed on an Applied Biosystems 3100-Avant Genetic Analyzer (Applied Biosystems, Foster City, CA). Sequence data were compared with the published sequence of SLC26A4 gene (ENSG00000091137) with the use of GeneTool Lite 1.0 software program (BioTools, Edmonton, Alberta, Canada).
RESULTS
A total of 32 SNHL patients with EVA, including 19 males and 13 females, were investigated (Table 1 ). Figure 1 shows a pedigree of a simplex case and the CT scan from a proband patient. All subjects had bilateral SNHL. One patient's audiometric data were not available ( Table 1 ). Audiogram of 10 patients (20 ears) shows a characteristic of conductive or mixed hearing loss in low frequencies (250 and 500 Hz) and SNHL in middle and high frequencies. The ABGs of 20 ears range from 15 to approximately 90 dB at 250 Hz and from 20 dB to approximately 60 dB at 500 Hz ( Table 2) . No mild hearing loss was found in the present study. A total of 48 percent (15 of 31) of patients with SLC26A4 mutations had profound loss, 36 percent (11 of 31) had severe loss, and 16 percent (five of 31) had moderate loss. Some patients with profound hearing loss may still have some measurable residual hearing, especially in low frequency. We consider the hearing loss progressive when the residual hearing continues to deteriorate in one or both ears. The symmetry of hearing loss detected in the 23 (74%) probands is reported in Table 1 . Twenty-two (69%) patients had a prelingual (Յ2 years of age) onset of hearing loss, with a mean age of onset of 1.02 years. Ten subjects were found to have progressive hearing loss. Average follow-up time was 9.5 years, with a range from one to 19 years. Six of the patients had fluctuating hearing loss.
A total of 13 different mutations were identified ( Table 3 ). The mutations were biallelic in 28 of the 32 subjects (88%). Of these, 11 subjects had homozygotic mutations, and 17 were compound heterozygotes. One case had complex allele with three variants. In four probands, only one SLC26A4 mutation was detected. Clinical characteristics are provided in Table 1 . The most common mutation was a splice site mutation in intron 7 (IVS7-2AϾG) found in 26 of 32 patients, which accounts for 60 percent (36 of 60) of the mutant alleles. The IVS7-2AϾG was detected in 10 homozygotes and 15 compound heterozygotes. Two cases were heterozygous with the second allele remaining unidentified. The 10 homozygous patients with IVS7-2AϾG had severe-to-profound deafness. Of the six patients with fluctuating hearing loss, five carried IVS7-2AϾG mutation in a compound heterozygous state and one was homozygous for IVS7-2AϾG. There was no clear relationship between genotype and phenotype identified.
The second most frequent mutation was p.H723R, accounting for 15 percent (nine of 60) of the mutant alleles. Overall, seven missense mutations, two splice site mutations, and four frameshift mutations were identified. Of these mutations, a total of five variants had not been previously reported, including two missense mutations (p.H135R and p.V545A) and three frameshift mutations (c.1555-1556delAA, c.1687-1692delA, and c.2082delA). None of these variants was detected in any of the 200 normal hearing subjects of Chinese background. A schematic distribution of the mutations identified in the present study and reported mutations among Chinese along the SLC26A4 gene is shown in Figure 2 .
Three different previously unreported mutations causing frameshifts with premature termination were detected in this study. The first new deletion is a two-base deletion of AA at nucleotide position 1555 to 1556 in exon 14. This mutation leads to a frameshift at codon 519, with a stop codon occurring at codon 539 or 20 amino acid residues downstream. This frameshift mutation was detected in a complex allele state with three variants (c.1548insC/c.1555-6delAA/ p.H723R) in a proband. The second novel frameshift mutation consists of a deletion of A at nucleotide position 1687 to 1692 in exon 15, which results in a frameshift, starting at codon 563, with a subsequent premature stop codon at the 572nd amino acid residue. The mutation was identified in a compound heterozygous state with a splice site mutation IVS7-2AϾG. Finally, the c.2082delA was also found in a compound heterozygous state with IVS7-2AϾG mutation. This mutation caused a frameshift at codon 694, resulting in a premature stop at codon 699 in exon 18.
In the present study, five missense mutations and one frameshift mutation, including c.1173CϾA/p.S391R, c.1174AϾT/p.N392Y, c.1226GϾA/p.R409H, c.1229CϾT/ p.T410M, c.2168AϾG/p.H723R, and c.1548insC, have been previously described. [3] [4] [5] [6] Two novel missense mutations were identified in the present study. The c.404AϾG/ p.H135R mutation was detected in a compound heterozygous state with the c.2168AϾG/p.H723R. The p.H135R change due to an AϾG transition at nucleotide position 404 in exon 4 results in a replacement of histidine, which has a positively charged imidazole functional group, with arginine, an amino acid with a positively charged guanidino group. This change occurs within the first extracellular domain of the SLC26A4 protein. Another new mutation, c.1634TϾA/p.V545A, was identified in a compound heterozygous state with IVS7-2AϾG. The two missense changes might be pathogenic on the basis of the following criteria: (1) these substitutions were absent in 200 unrelated control DNA samples of Chinese background; (2) the two newly identified missense changes are located within functional domains of the SLC26A4 protein; and (3) sequence comparison across species demonstrates conservation of the p.H135 and p.V545 residues in humans, rats, mice, and xenopus (Fig 3) . 5  20  80  60  50  80  30  20  80  60  50  80  30  10  45  70  25  65  105  40  40  65  25  60  85  25  13  25  70  45  40  70  30  25  80  55  40  80  40  15  35  100  65  50  90  40  35  100  65  50  100  50  16  15  70  55  55  85  30  15  60  45  40  85  45  18  10  60  50  40  70  30  10  55  45  40  60  20  28  0  50  50  25  70  45  0  75  75  25  85  60  29  0  60  60  20  65  45  0  90  90  20  80  60  30  25  65  40  25  70  45  20  35  15  20  50  30  31  5  60  55  20  50  30  5  60  55  10  40 the Spanish population, the most frequent mutation is p.Q514K (17%). 11 To date, more than 40 mutations have been reported among the Chinese (Fig 2) . IVS7-2AϾG mutation was the most common mutation, accounting for 22 percent to 58 percent of all the mutant alleles in Chinese patients with hearing loss associated with EVA or both EVA and Mondini dysplasia. [7] [8] [9] Wang et al 7 reported that biallelic mutations were identified in 88 percent of patients from the simplex families. Overall, up to 98 percent of patients were Table 3 Details of genotypes of SLC26A4 detected in 32 SNHLs associated with EVA patients in a Chinese population found to have at least one possible pathogenic variant in SLC26A4. The IVS7-2AϾG mutation accounted for 58 percent (102 of 177) of all the mutant alleles. The IVS7-2AϾG mutation caused skipping of exon 8 with a resulting stop codon at position 311, leading to a predicted truncated protein.
The mutation was first reported in a Turkish family 12 and subsequently detected in deaf subjects from Japan, Korea, and China. IVS7-2AϾG has not been found in Western populations, including deaf patients in the United States (http://www.healthcare.uiowa.edu/labs/pendredandBor/ slcMutations.htm). Dai et al 8 have recently reported a comprehensive study of the prevalence of IVS7-2AϾG mutation in an analysis of 3271 deaf subjects from 27 regions of 24 provinces of China. The detection rate was found to range from 28 percent to less than 1 percent according to ethnicity. The results showed that a genetic test for the IVS7-2AϾG mutation alone would identify the molecular cause in up to 8 percent to 12 percent of deaf patients in a few eastern and central regions of China. However, the IVS7-2AϾG mutation occurs at a much lower frequency (0.000-0.019) among ethnic groups in the southwest and northwest regions of China. The data suggest that for subjects who are negative for the IVS7-2AϾG mutation, further mutational analysis of the full SLC26A4 gene or other deafness-related genes will be necessary.
In the present study, the prevalence of SLC26A4 mutation was 100 percent (32 of 32) in this cohort of Chinese patients with bilateral EVA. Biallelic mutations were detected in 88 percent (28 of 32) of patients, 11 of whom were homozygous. Four subjects were found to carry a single SLC26A4 mutation. We identified SLC26A4 mutations in 60 of the 64 alleles tested (94%; Table 3 ). The IVS7-2AϾG mutation was the most common form, accounting for 60 percent (36 of 60) of all the mutant alleles, which supports the view that the IVS7-2AϾG mutation is indeed the most common mutation found in genetic deafness patients of Chinese background who have EVA. Thus, if screening for mutations in SLC26A4 is considered, it is reasonable to screen for the IVS7-2AϾG mutation first. A total of five new mutations were identified in this study, including two missense mutations and three frameshift mutations. The distribution of the five novel mutations described in the present study along the SLC26A4 gene is shown in Figure 2 : the c.404AϾG/p.H135R mutation occurs in the first extracellular region; two of the mutations (c.1555-6delAA; c.1634TϾA/p.V545A) are located in the cytoplasmic domain; the c.1687-92delA is detected in the transmembrane domain; and the c.2082delA mutation was found within the sulfate transporter and antisigma antagonist (STAS) domain at the C-terminal region of the protein, which seems to be involved in binding of nucleotides and/or interaction with the cyclic adenosine monophosphate-dependent chloride channel cystic fibrosis transmembrane conductance regulator. 13 The STAS domain is proposed to be important for proper localization to the plasma membrane 14 and regulation of anion transport activity. 13, 15 Identification of the role of SLC26A4 in nonsyndromic deafness with EVA may allow us to investigate any possible genotype-phenotype relation by combining a molecular genetic study and an audiological analysis. In the present study, the following features of the SLC26A4-related deafness were observed. The hearing impairment in 69 percent of the patients had a prelingual onset. The degree of hearing loss varies greatly, ranging from moderate to profound, but a higher prevalence of severe and profound hearing loss was found. We have not found any correlations between the type of SLC26A4 mutations and the audiogram. There are significant proportions of patients with asymmetric (26%), progressive (32%), or fluctuating hearing loss (21%). These audiological features are not common in other recessive forms of nonsyndromic hearing loss. Clearly, more cases and comprehensive audiological studies are needed to address any potential genotype and phenotype correlation.
CONCLUSION
Our data confirm the high prevalence of SLC26A4-related deafness in Chinese patients with SNHL and EVA and support the view that the PDS gene in the Chinese population has a unique spectrum of mutations that is distinct from that found in the other ethic populations. All categories of hearing loss severity, except for mild loss, were found. SLC26A4-related deafness appears to be prevalent in severe-to-profound loss. Although no clear genotype and phenotype correlation was found, high incidence of asymmetric, progressive, and fluctuating hearing loss detected in the current study warrants further investigations to define any molecular basis/environmental factor for these uncommon features in nonsyndromic forms of recessive deafness. The high detection rate of SLC26A4 mutations in Chinese subjects with SNHL and EVA indicates that screening SLC26A4 mutations should be offered to deaf Chinese patients with EVA.
